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The heart has the ability to grow in size in response to
exercise, but little is known about the transcriptional
mechanisms underlying physiological hypertrophy.
Adult cardiomyocytes have also recently been
proven to hold the potential for proliferation, a pro-
cess that could be of great importance for regenera-
tive medicine. Using a unique RT-PCR-based screen
against all transcriptional components, we showed
that C/EBPb was downregulated with exercise,
whereas the expression of CITED4 was increased.
Reduction of C/EBPb in vitro and in vivo resulted in
a phenocopy of endurance exercise with cardiomyo-
cyte hypertrophy and proliferation. This proliferation
was mediated, at least in part, by the increased
CITED4. Importantly, mice with reduced cardiac
C/EBPb levels displayed substantial resistance to
cardiac failure upon pressure overload. These data
indicate that C/EBPb represses cardiomyocyte
growth and proliferation in the adult mammalian
heart and that reduction in C/EBPb is a central signal
in physiologic hypertrophy and proliferation.INTRODUCTION
Cardiac muscle adapts to increased pressure and/or volume
with hypertrophy. This holds true for physiological stimuli, such
as exercise, as well as for pathological provocations, including
hypertension. Though the earliest stages appear quite similar
at a morphological level, pathological cardiac hypertrophy leads
to cardiovascular diseases such as heart failure and arrhythmia,
whereas physiological hypertrophy does not. Thus, under-
standing the mechanistic distinction between these two types
of cardiac growth has very important clinical implications.
Numerous prior reports document transcription factors involved
in pathological hypertrophy (Akazawa and Komuro, 2003; Frey1072 Cell 143, 1072–1083, December 23, 2010 ª2010 Elsevier Inc.and Olson, 2003), but relatively little is known about the molec-
ular mechanisms controlling physiological hypertrophy.
Cardiomyocytes in adult mammals retain a limited ability to
proliferate in response to specific stimuli (Bergmann et al.,
2009; Bersell et al., 2009; Kajstura et al., 2010). This has potential
importance because cardiomyocyte proliferation could serve as
a basis for regeneration of an injured heart if it could be enhanced
and harnessed. However, whether this process can be modu-
lated through physiological interventions remains unclear. More-
over, whereas recent studies have implicated some signal trans-
duction pathways involved in adult cardiomyocyte proliferation
(Bersell et al., 2009), little is known about the detailed molecular
mechanisms and particularly the transcriptional components
that are decisive in this process. Furthermore, there is little
data available on factors that control cardiomyocyte proliferation
in the adult heart.
One of few known regulators of cardiomyocyte proliferation is
Gata4, which was recently reported to mark proliferative cells
during cardiac regeneration in the zebrafish (Kikuchi et al.,
2010). This factor is also a well-known regulator of cardiomyo-
cyte differentiation in adult hypertrophy, together with SRF,
Nkx2.5, Tbx5, and Gata6 (Akazawa and Komuro, 2003).
Here, we studied a murine model of physiological hypertrophy
induced by endurance exercise, using a method termed
Quanttrx, which we recently developed for genome-wide, quan-
titative measurement of the expression of all transcriptional
components (Gupta et al., 2010). The database underlying this
method includes all known transcription factors, transcriptional
coregulatory proteins, and all proteins that contain a motif that
has been associated with transcriptional components, whether
their function is known or not. We report here that endurance
exercise effected a hypertrophic and proliferative program in
cardiomyocytes, which was dependent on a reduction in the
expression of the transcription factor C/EBPb, and a linked
increase in the expression of CITED4. Furthermore, mice with
genetically reduced C/EBPb levels recapitulated many of the
cardiac phenotypes seen in exercised mice. Importantly, mice
with reduced C/EBPb were resistant to the development of
cardiac dysfunction in response to pressure overload on the
heart.
Figure 1. A Swim Model Induces Physiological
Cardiac Hypertrophy and Cardiomyocyte Prolifer-
ation
(A) Mice swam using a ramp protocol for 2 weeks with
respective controls (n = 4) and were assayed for PCNA
protein levels with subsequent quantification. Data are
presented as PCNA per a-tubulin after subtraction of
background. Data are representative for two independent
mouse cohorts.
(B and C) Representative image and quantification of Ki67
(B) and phosphohistone3 (C) staining from exercised mice
(green) counterstained with a-actinin (red) and DAPI (blue)
in cardiac tissue.
(D) Exercised and control mice were injected with BrdU
3 days prior to the final exercise day. The image shows
a representative section from the exercised cohort. BrdU
is labeled in green, a-actinin in red, and DAPI in blue.
(E) Representative image and quantification of Aurora B
kinase (green) staining from exercised mice counter-
stained with a-actinin (red) and DAPI (blue) in cardiac
tissue. All quantifications were based on at least 80
(blinded) images from each group (from at least four
mice). Any uncertainty concerning whether a ki67-,
AuroraB-, or BrdU-positive cell was completely within an
a-actinin-positive area was resolved using confocal
Z stacks.
Error bars represent standard error of mean. *p < 0.05
versus respective control using Student’s t test. See also
Figure S1.RESULTS
Cardiac Hypertrophy and Cardiomyocyte Proliferation
Are Induced following Endurance Exercise
To study transcriptional regulators of physiological cardiac
hypertrophy, a ramp swimming exercise model was used
(Taniike et al., 2008). As shown in Figure S1 (available online),
mild cardiac hypertrophy was induced without alterations in
the expression of pathological gene markers such as ANP and
BNP. There was also a 45% increase in cardiomyocyte cell
size (Figure S1) without any detectable difference in fibrosis or
angiogenesis (Figure S1). Hence, we may conclude that healthy
physiological cardiac hypertrophy occurred in these animals.
Further characterization revealed that expression of the cell
proliferation marker PCNA was increased in the hearts from
exercised mice (Figure 1A). To establish the cellular origin of
the increased proliferation markers, confocal microscopy was
employed in cardiac tissue stained for both the cardio-
myocyte-selective protein a-actinin and the proliferation markerCell 143, 1072–10ki67. Robust ki67 staining was seen in 1%–5%
of cardiomyocytes (Figure 1B). Importantly,
there was a significant increase in cardiomyo-
cyte ki67 staining in the exercised mice
compared to the nonexercised controls, as
judged from blinded analyses of histological
sections using digital software. The more
specific mitosis marker, phospho-Histone3
(pH3), was also elevated (Figure 1C), though
the absolute number of positive cells was rela-
tively low. Figure S1 shows pH3-positive cardi-
omyocytes in the different stages of mitosis. Thus, markers of
both cell size and proliferation are elevated in the cardiomyo-
cytes of mice in this model of physiological hypertrophy.
Previous studies have utilized the density of cardiomyocyte
nuclei as an indicator of cardiomyocyte proliferation (Bersell
et al., 2009). We could detect a small increase in nuclear density
(100% and 132% in controls versus exercised mice, respec-
tively; p = 0.07), but this did not reach statistical significance.
However, it is worth noting that the observed increase in cardio-
myocyte size would be expected to confound/dilute the
calculated changes in nuclear density. DNA biosynthesis was
therefore assayed using bromodeoxyuridine (BrdU) injections
in mice undergoing this exercise protocol. We could detect
double-a-actinin and BrdU-positive cardiomyocytes at a
frequency of 1%–6% in exercised mice. Figure 1D shows
a substantial increase in BrdU-positive cardiomyocytes in the
hearts of exercised mice compared to the controls. Importantly,
Z stack visualization of positive cells clearly demonstrates
a distinct cardiomyocyte localization of the BrdU (Figure S1).83, December 23, 2010 ª2010 Elsevier Inc. 1073
Finally, staining for the cytokinesis marker Aurora B kinase was
used to demonstrate that the exercise protocol did indeed
promote completed cardiomyocyte cell division (Figure 1E).
Conversely, we could not detect any of these changes in prolif-
eration markers in a murine model of pathological hypertrophy
(data not shown). Taken together, these data strongly suggest
that adult cardiomyocytes increase in both size and proliferation
rate in response to this form of endurance exercise.
C/EBPb Is Downregulated during Physiological
Hypertrophy
To investigate the transcriptional basis of physiological cardiac
hypertrophy, we utilized Quanttrx, a qPCR-based screen that
we recently developedagainst all knownandpredicted transcrip-
tional components (Gupta et al., 2010).We used cardiac samples
from the mice characterized (above) together with cardiac
samples from mice subjected to transaortic constriction (TAC)
for 2 weeks. As shown in Figure S1, the TAC procedure induced
a similar degree of hypertrophy as seen in the exercised animals
but with elevation of ANP/BNP, thus indicating pathological
hypertrophy. There were no signs of heart failure or other patho-
logical changes in the mice subjected to TAC at this time point.
The Quanttrx screen identified 175 genes significantly regu-
lated in theexercisemodel and96 in thepathological (TAC)model
(TableS1andTableS2). Importantly, therewas little overlap in the
expression profile between the two models. In fact, there was
a significant, negative correlation between the changes induced
in the respective model (Figure S2; r = 0.32; p < 0.001). Thus,
these models of pathological and physiological hypertrophy
express distinct programs of transcriptional components.
Of the 175 transcription factors regulated by physiological
hypertrophy, 47 (27%) had no known function (no PubMed
annotation). However, 10 transcription factors with known func-
tions in cardiac differentiation and/or adult hypertrophy were
differentially regulated in the swim model. These included well-
known genes such as Nkx2.5, Gata4, Tbx5, Mef2c, and Gata6.
Furthermore, 13% of the differentially expressed factors had
known or suggested roles in cellular proliferation. Less than
1% of the genes regulated in the pathological model had any
known role in cellular proliferation.
Based on the magnitude of expression changes and absolute
cardiac expression, we chose 30 genes out of this preliminary list
of 272 and performed qPCR analyses in completely new
samples of either physiological (endurance exercise) or patho-
logical (TAC) hypertrophy. Eight out of these 30 showed robust
validation (Figure S2 and Figure 2A), and these were further
analyzed for cardiomyocyte-specific expression. Figure S2
shows expression of these genes in cardiomyocytes and non-
cardiomyocytes after density gradient separation. Five out of
eight were expressed primarily in the cardiomyocyte fraction,
and these were subsequently analyzed using adenoviral-medi-
ated forced expression and/or siRNA-mediated knockdown,
using changes in cell size of rat neonatal cardiomyocytes as
our endpoint. Gbx2, Cited4, Mlx, and Meox1 failed to demon-
strate any effect on cardiomyocyte sizes (Figure S2), but reduc-
tion of C/EBPb caused a clear increase in cell size (Figure 3A).
C/EBPb is a member of the bHLH gene family of DNA-binding
transcription factors and has known roles in cell proliferation and1074 Cell 143, 1072–1083, December 23, 2010 ª2010 Elsevier Inc.differentiation in other tissues (Sebastian and Johnson, 2006),
including adipose cells and liver. However, it has not been
studied in the context of the cardiomyocyte. C/EBPb mRNA
expression was reduced by 61% in hearts in the exercise model
when assayed in new samples, but this effect was not observed
in a model of pathological hypertrophy using transverse band-
ing (TAC) performed in parallel (Figure 2A). Downregulation of
C/EBPb was also seen in response to the exercise training at
the protein level (Figure 2B). Expression of the short LIP
C/EBPb isoform that is inhibitory toward C/EBPb function was
undetectable in these cardiac samples (Figure 2B). Confocal
microscopy illustrated that it was indeed cardiomyocyte-specific
expression of C/EBPb that was reduced with exercise (Fig-
ure 2C). Consistent with this, C/EBPb expression was enriched
in the cardiomyocyte fraction, versus noncardiomyocyte cells,
following gradient purification of rat neonatal cardiomyocytes
(Figure 2D and Figure S2).
Two additional mouse models of exercise were tested for
effects on C/EBPb expression: acute and low-intensity treadmill
running. Neither treatment resulted in cardiac hypertrophy (data
not shown), but reduction of C/EBPb expression occurred in the
acute setting (40 min of treadmill running), as seen in Figure 2E.
Thus, C/EBPb expression is reduced relatively early in endur-
ance exercise.
Reduction in C/EBPb Expression Induces Hypertrophy
and Proliferation in Cultured Cardiomyocytes
The functional consequences of experimental reduction of
C/EBPb were assessed in detail in primary rat cardiomyocytes.
An siRNA was used to reduce C/EBPb levels to approximately
the levels of mRNA observed after endurance exercise (43%)
(Figure S3). As demonstrated in Figures 3A and 3B, the forced
decrease in C/EBPb mRNA was sufficient to drive an increase
in cell size and in the rate of protein biosynthesis. No statistically
significant change in cell size or protein biosynthesis was seen
with forced C/EBPb expression (p = 0.42 and p = 0.054, respec-
tively). The reduction of C/EBPb expression was also sufficient to
ablate the increase in ANP levels seen with pathological provo-
cation (Figure S3).
Interestingly, the C/EBPb reduction via siRNA also led to an
increase in cell number (Figure 3C). This was accompanied by
increased PCNA expression and increased BrdU incorporation
into DNA, highly suggestive of cardiomyocyte proliferation
(Figures 3D and 3E). These data indicate that a reduction in
C/EBPb expression is sufficient to induce hypertrophy and prolif-
eration in cultured cardiomyocytes.
C/EBPb Regulates Expression of a Gene Set
Characteristic of Physiological Hypertrophy
by Sequestering Serum Response Factor
The initial Quanttrx screen revealed a specific set of regulated
genes with known functions in cardiomyocyte differentiation
and hypertrophy (Figure 4A and Table S1). Examples of such
genes were Gata4, Tbx5, and Nkx2.5, which all induce hyper-
trophy (Akazawa and Komuro, 2003). Beyond these 11 genes,
we also investigated expression levels of the genes that are
well known to be altered in cardiac hypertrophy or differentiation,
including a-MHC, TnI, and TnT, which were all upregulated in the
Figure 2. C/EBPb Is Expressed in Cardiomyocytes
and Downregulated with Endurance Exercise
(A) Cardiac C/EBPbmRNA levels in a model for physiolog-
ical (swim) and pathological (TAC) hypertrophy with
respective controls (n = 4) as described in methods.
(B) Western blot analysis of C/EBPb and b-actin in the
swim cohort (above) with subsequent quantification.
Data are presented as percent of control with C/EBPb
relative to b-actin after background subtraction.
(C) Confocal microscopy after immunohistochemistry
against C/EBPb (green), a-actinin (red), and DAPI (blue)
in cardiac tissue with subsequent quantification in indi-
cated groups. Data are presented as the ratio of
C/EBPb-positive cardiomyocyte nuclei.
(D) Gradient fractionation of primary rat neonatal cardiac
cells followed by expression analysis of cardiomyocyte
and fibroblast markers.
(E) Cardiac C/EBPbmRNA levels from three different exer-
cise regimens: acute = 40 min treadmill running (n = 6);
‘‘low intensity’’ = 2 weeks of 30 min daily running (n = 6);
‘‘endurance’’ = the swimming protocol as described in
methods (n = 4).
Error bars represent standard error of mean. *p < 0.05
versus respective control using Student’s t test. See also
Figure S2.hearts of exercised mice (Figure 4A). The transcriptional coregu-
lator PGC-1a has previously been demonstrated to have an
important role in preventing cardiac dysfunction after the devel-
opment of hypertrophy (Arany et al., 2006), and exercised mice
indeed displayed increased cardiac expression levels of PGC-
1a together with its downstream targets VEGF, Ndufs1, Ndufv2,
and ATP5o (Figure 4A). Thus, by combining the Quanttrx screen
hits with markers of hypertrophy and the PGC-1a, as well as its
downstream targets, we defined an exercise-induced gene set
of 19 genes (Figure 4A). The changes in mRNA expression for
Nkx2.5, Tbx5, Mef2c, Gata4, and PGC-1a following TAC surgery
are shown in Figure S4.
As shown in Figure 4B, reduction in C/EBPb levels in primary
cardiomyocytes resulted in a strikingly similar expression pattern.
In fact, 11/19of thesegeneswere regulated in thesamemanner as
in the exercise model (p < 0.001 using chi-square statistics).
Furthermore, adenoviral expression of C/EBPb induced essen-
tially the reverse expression pattern (Figure S4). These data
strongly suggest that C/EBPb acts upstream of other transcrip-Cell 143, 1072–10tional components that are also regulated in
physiological hypertrophy. Especially interesting
was the C/EBPb-dependent regulation of Gata4,
which has recently been demonstrated to play
amajor role in zebrafish cardiomyocyte prolifera-
tion during myocardial regeneration (Kikuchi
et al., 2010).
Many of the genes regulated by both
endurance exercise and the siRNA-mediated
C/EBPb reduction are known to be transcrip-
tional targets of the transcription factor SRF,
with SRE elements in their promoters (Akazawa
and Komuro, 2003). C/EBPb has been demon-
strated to physically interact with SRF (Hanlon
and Sealy, 1999), but the functional consequences of this interac-
tion are not clear, especially in cardiomyocytes inwhich the role of
C/EBPb is unknown.Previous reportson theC/EBPb-SRF interac-
tion have suggested a positive effect on SRE-dependent
elements, but the increased expression levels of Gata4 and
a-MHC (Figure 4A) following C/EBPb siRNA here suggested
anegative regulationofSRE-dependentgenes incardiomyocytes.
A physical interaction between the SRF and C/EBPb proteins
was indeed observed using coimmunoprecipitation fromprimary
cardiomyocytes (Figure 4C). Next, chromatin immunoprecipita-
tion (ChIP) assays were performed, examining the binding of
SRF to the Gata4 and a-MHC promoters following gain and
loss of the C/EBPb protein. As shown in Figure 4D, CEBPb
reduction using siRNA dramatically increased SRF binding to
the promoters of both a-MHC and Gata4, in which SRF is known
to play a positive regulatory role. Conversely, adenoviral expres-
sion of C/EBPb reduced SRF binding to these promoters. Thus,
C/EBPb interferes with SRF binding to the promoters of critical
cardiac genes (Figure 4E).83, December 23, 2010 ª2010 Elsevier Inc. 1075
Figure 3. Reduction of C/EBPb in Primary Cardio-
myocytes Results in Hypertrophic Cell Growth and
Proliferation
Primary rat neonatal cardiomyocytes treated with either
a C/EBPb siRNA or a C/EBPb-expressing adenovirus
with respective controls. All experiments were performed
48 hr after transfection/transduction.
(A) Immunohistochemistry against a-actinin followed by
cell area quantifications as described in methods. At least
100 cells were quantified in all groups.
(B) Protein biosynthesis measured as 35S-Met incorpora-
tion into the protein pool after a 1 hr pulse. Data are pre-
sented as percent of control.
(C) Quantification of cell numbers in primary after transfec-
tion with indicated siRNA constructs.
(D) Western blot analysis of PCNA followed by quantifica-
tion (n = 4). Data are presented as PCNA relative to b-actin
after background subtraction.
(E) Primary rat neonatal cardiomyocytes were treated with
BrdU 24 hr after transfection with indicated siRNA. Cells
were then stained against BrdU and a-actinin, and
BrdU-positive cardiomyocytes were counted and normal-
ized to total number of cardiomyocytes.
Errorbars representstandarderrorofmean. *p<0.05versus
respective control usingStudent’s t test. See also FigureS3.The recent discovery of the ErbB4 pathway in cardiomyocyte
proliferation led us to investigate whether C/EBPb could be
affected by such signaling. This was especially interesting as
ErbB4 signals via AKT1, a kinase known to function in physiolog-
ical hypertrophy (DeBosch et al., 2006). We thus investigated the
connection of this pathway to C/EBPb using both forced expres-
sion of wild-type AKT1 and a dominant-negative AKT1 (Nagoshi
et al., 2005). As demonstrated in Figure S4, increasing AKT1
activity did indeed reduce C/EBPb expression levels together
with an expression profile resembling what was observed with
exercise with increased expression of Tbx5, Gata4, TnI, and
a-MHC. Conversely, the dominant-negative AKT1 mutant
increased C/EBPb in parallel with decreased mRNA levels of
Tbx5, Gata4, TnI, TnT, and a-MHC. We could thus conclude
that AKT1 activity evokes the same gene expression profile as
seen in exercise. We next used C/EBPb adenovirus together
with AKT1 overexpression to establish whether C/EBPb indeed1076 Cell 143, 1072–1083, December 23, 2010 ª2010 Elsevier Inc.act downstream on AKT1 in the regulation of
these target genes. As demonstrated in Fig-
ure S4, C/EBPb overexpression ablated the
positive expression effects of AKT1 on Tbx5,
Gata4, TnI, TnT, and a-MHC. Taken together,
these data suggest that AKT1 regulates
C/EBPb expression, connecting C/EBPb to
a previously characterized physiological growth
pathway in the heart.
C/EBPb Negatively Regulates CITED4,
a Transcription Factor Promoting
Cardiomyocyte Proliferation
The SRF-dependent gene set described above
includes well-known regulators of cardiomyo-
cyte hypertrophy, but apart from Gata4, theyare not known to participate in a proliferative phenotype, such
as we see with C/EBPb reduction. We thus analyzed the list of
exercise-induced cardiac genes (Figure S2) for those controlled
by C/EBPb that might influence or control cardiomyocyte prolif-
eration. Preliminary studies using gain and loss of function for six
factors apparently downstream of CEBPb led us to focus on
CBP/p300-interacting transactivator with ED-rich carboxy-
terminal domain 4 (CITED4). Indeed, CITED4 showed a robust
increase in exercised hearts (Figure 5A), and its expression level
wasmarkedly altered with C/EBPb gain or loss of function in vitro
(Figure 5B).
Strikingly, forced CITED4 expression (Figure S5) increased
cardiomyocyte cell numbers together with an increased
percentage of ki67-positive cells (Figures 5C and 5D).
Conversely, siRNA directed against CITED4 (Figure S5C)
reduced both cell numbers and ki67 staining (Figures 5C and
5D). Gene expression analysis also revealed a gene set of
Figure 4. C/EBPb Controls an Exercise-Induced
Gene Set by Inhibiting SRF DNA Binding
(A and B) QPCR analysis of indicated genes in hearts from
endurance-exercised mice (A) and in primary cardiomyo-
cytes treated with C/EBPb or control siRNA for 48 hr (B).
*p < 0.05 versus respective control using Student’s t test.
(C) Immunoprecipitation against SRF or a nonimmune IgG
in primary cardiomyocytes followed by western blot
against SRF, C/EBPb, and the control protein a-tubulin
as indicated.
(D and E) Chromatin immunoprecipitation in primary cardi-
omyocytes treated with either C/EBPb siRNA (D) or
C/EBPb adenoviral overexpression (E) with respective
controls. Precipitated DNA was then analyzed with RT-
PCR using primers directed against promoter regions in
the Gata4 and myh6 gene. ChIP experiments were
repeated at least three times with similar results.
Error bars represent standard error of mean. *p < 0.05
versus respective control using one-way ANOVA statis-
tics. See also Figure S4.proproliferative genes increased in endurance exercise (Fig-
ure S5), in which the important cell cycle/proliferation factors
CyclinD1 and n-myc also displayed increased expression with
forced CITED4 expression together with SRF (Figure S5).
To investigate the functional relationship betweenC/EBPb and
CITED4, we used siRNA directed against CITED4 together with
C/EBPb siRNA.As shown in Figure 5E,CITED4knockdowncould
completely abolish the effect of cellular proliferation seenwith the
C/EBPb reduction. Thus, C/EBPb is likely to mediate its antipro-
liferative effects, at least in part, via CITED4 expression.
C/EBPb Controls Cardiomyocyte Proliferation
in the Zebrafish Embryo
We next tested the role of C/EBPb reduction in zebrafish,
a simple and experimentally accessible in vivo system. Anti-
C/EBPb morpholino oligonucleotides were injected into zebra-
fish embryos transgenic for cmlc2-GFP at the one-cell stageCell 143, 1072–10(Figure 6A). Figure 6B shows zebrafish hearts
dissected at 36 hr and stained for nuclei (DAPI,
blue) and plasma membrane (integrin, red).
Quantification of these images revealed
increased cardiomyocyte cell number but did
not change cardiomyocyte size up to 72 hr post-
fertilization (Figure 6D). Furthermore, 20 min
BrdU labeling of 48 hr hpf embryos demon-
strated increased DNA synthesis (Figure 6C
and quantification in Figure 6E). Of note, Gata4
mRNA expression was significantly increased,
consistent with results shown above (Figure 6F).
Thus, reduction of C/EBPb induces cardiomyo-
cyte proliferation in zebrafish hearts in vivo.
Heterozygosity for C/EBPb in Mice
Mimics Cellular Aspects of Endurance
Exercise and Is Cardioprotective against
Pressure Overload
Mice with a complete loss of C/EBPb show pre-
and perinatal lethality, but heterozygotes arerelatively normal. Mice heterozygous for C/EBPb have cardiac
C/EBPb mRNA levels reduced to a similar level as observed in
exercisedmice (50% reduction) (Figure S6). These heterozygous
animals were therefore used to study the role of this factor
in mammalian cardiac function. The exercise-induced gene set
defined above was analyzed in hearts of the C/EBPb+/ com-
pared to wild-type littermates, and a pattern of expression
changes similar to that seen with exercise was seen for multiple
genes (8 of 19 genes) (Figure S6). Furthermore, measurements of
cell size (done in a blinded manner) revealed cardiomyocyte
hypertrophy (Figure 7A) and an increase in heart weight (Fig-
ure S6). Echocardiographic studies revealed a small but signifi-
cant increase in fractional shortening, an important parameter
of improved heart function (Table S3). No differences in heart
wall thickness were observed.
Cardiomyocyte proliferation was also assayed at baseline
in the C/EBPb+/ mice. Notably, there was a clear increase in83, December 23, 2010 ª2010 Elsevier Inc. 1077
Figure 5. CITED4 Is Upregulated with Endurance Exercise, Regu-
lated by C/EBPb, and Its Forced Expression Induced Cardiomyocyte
Proliferation In Vitro
(A) mRNA levels of cardiac CITED4 in control and endurance-exercised (swim)
mice normalized to 18S expression.
(B) mRNA expression of CITED4 in primary rat neonatal cardiomyocytes after
siRNA knockdown (left) or adenoviral overexpression (right) of CITED4.
Expression levels are normalized to 18S.
(C and D) Rat neonatal cardiomyocytes treated with either an adenovirus over-
expressing CITED4 (left) or a siRNA directed against CITED4 (right). Cells were
then stained against a-actinin and ki67, and positive cells were counted in 203
view fields from 15 random images per group.
(E) Rat neonatal cardiomyocytes treated with control siRNA, C/EBPb siRNA +
control siRNA, or C/EBPb siRNA + Cited4 siRNA, followed by assay of BrdU
incorporation as previously described. Data is pooled from three experiments
and presented as percent of control.
Error bars represent standard error of mean. *p < 0.05 versus respective
control, and x versus C/EBPb siRNA using one-way ANOVA statistics. T test
was used for (A–D). See also Figure S5.cardiomyocyte nuclear density (Figure 7B), consistent with
increased expression of proliferation markers in the cardiomyo-
cytes that was also observed (Figure S6). BrdU injections
resulted in an increased number of positive cardiomyocytes in
theC/EBPb+/mice (Figure 7C and Figure S6). We also detected
Aurora B kinase-positive cardiomyocytes in C/EBPb+/ cardiac
tissue (Figure 7D). To study adult cardiomyocyte proliferation
directly, we also isolated adult cardiomyocytes from C/EBPb+/1078 Cell 143, 1072–1083, December 23, 2010 ª2010 Elsevier Inc.mice and littermate controls, incubated them in culture with
BrdU for 48 hr, and stained for proliferation markers. Fewer
than 0.05% ± 0.1% of cardiomyocytes from control mice
were BrdU positive. However, cells from the C/EBPb+/ mice
displayed a 10-fold increase in positive nuclear staining
(0.6% ± 0.2% of cells; p < 0.05 compared to control) (Figure 7E).
We next performed the exercise protocol on the C/EBPb+/
mice together with littermate controls. As shown in Figure S7,
there was no further reduction in C/EBPb levels with exercise
in the C/EBPb+/ mice compared to wild-types. In addition, we
could only detect a minor increase in heart mass in the exercised
C/EBPb+/ mice (Figure S7). More interestingly, however, the
C/EBPb+/ mice displayed a clear increase in exercise capacity
at baseline (Figure S7), suggestive of a functional consequence
of C/EBPb reduction in vivo.
To critically assess the possible protective role of the cardiac
changes seen in the C/EBPb+/ mice, we performed transverse
aortic constriction (TAC) to induce pressure overload on the
heart leading to pathological cardiac hypertrophy and dysfunc-
tion in mice. As expected, TAC resulted in progressive reduction
in cardiac function, as judged by fractional shortening (FS) in the
wild-type mice. However, the C/EBPb heterozygous mice dis-
played only a minor reduction in contractile function after TAC
(Figure 7F). Pulmonary edema is a very important characteristic
of cardiac failure in bothmice and humans, and the differences in
heart function between the two groups were also supported by
a significant difference in lung weight (Figure 7G). Ventricular
dilatation (as a marker of cardiac failure) also increased more
rapidly in the wild-type mice than in the C/EBPb+/ animals
(Figure S7).
According to our IACUC rules, mice subjected to TAC had to
be sacrificed when cardiac function (fractional shortening)
decreased by at least four standard deviations from the mean,
as this represents a very substantial deterioration likely to be
associated with heart failure. Using such criteria, Kaplan-Meier
analysis demonstrated that wild-type littermates were signifi-
cantly more likely to develop this degree of cardiac dysfunction
after TAC than C/EBPb+/ littermates (Figure 7H). Thus, the
reduction in C/EBPb expression in the hearts of heterozygous
mice, quantitatively comparable to that seen after exercise
training, results in improved cardiac function and resistance to
a heart-specific pathological stress.
DISCUSSION
Despite the well-documented beneficial cardiovascular effects
of exercise, our understanding of the mechanisms underlying
these benefits, particularly in the heart, remains very limited. In
particular, little is known about the transcriptional pathways
underlying physiological hypertrophy, as compared to the wide
variety of transcription factors implicated in pathological hyper-
trophy. Here, we provide evidence for a cardiac pathway
induced by exercise and mediated by the reduction of
C/EBPb, resulting in physiological hypertrophy. Interestingly,
exercise or experimental decreases in C/EBPb expression
induce increases in both cardiomyocyte size and cell division,
which are likely to contribute to some of the benefits observed.
Moreover, these effects were tightly coupled to a beneficial
Figure 6. C/EBPb Reduction in the Zebrafish
Embryo Results in Cardiomyocyte Proliferation
An anti-C/EBPb morpholino was injected into one-cell
stage cmlc-GFP transgenic zebrafish embryos.
(A) Western blot analysis against indicated proteins in ze-
brafish embryos 48 hpf.
(B) Dissection of beating hearts at 36 hr followed by integ-
rin staining (blue = DAPI, green = GFP, and red = zn-8).
(C) Twenty minutes BrdU labeling prior to dissection of
beating hearts and BrdU (green)/zn-8 (red) staining.
(D) Quantification (B) from totally 30 hearts per group.
(E) Quantification of integrin- and BrdU-positive cardio-
myocytes (C) from n = 6 embryos per group. Data are pre-
sented as percent of control and representative of two
independent experiments.
(F) RT-PCR analysis of indicated transcripts.
Error bars represent standard error of mean. *p < 0.05
versus respective control using Student’s t test. See also
Figure S6.metabolic gene set, including an induction of the PGC1a
pathway. Lastly, we observe that reduction in C/EBPb expres-
sion was itself sufficient to result in improved cardiac function
and resistance to pathological changes/lethality induced in the
heart by pressure overload.
Considerable attention has recently been focused on the
potential for cardiomyocytes to proliferate, illustrated in several
recent papers (Bergmann et al., 2009; Bersell et al., 2009;
Kajstura et al., 2010). In fact, the proliferative behavior ob-
served here in cardiomyocytes caused by the endurance
exercise was quantitatively similar to that seen with NRG1 treat-
ment previously (Bersell et al., 2009). Data presented here also
suggest that C/EBPb is an important functional target of
ErbB4-related signaling pathways, particularly AKT1, in
cardiomyocytes.
Exercise and genetic reduction of C/EBPb both resulted in
the induction of a specific gene set in vitro and in vivo that is
known to influence cardiac function. Tbx5, Nkx2.5, Gata4,Cell 143, 1072–10and a-MHC have all been demonstrated to
induce hypertrophy in adult cardiomyocytes
(Akazawa and Komuro, 2003). It is thus likely
that C/EBPb exerts part of its hypertrophic
actions via increases in this important gene
set. It is also worth noting that these effects
of reduced C/EBPb expression do not require
massive changes in mRNA or protein levels;
50%–60% changes through exercise or
genetic alterations are sufficient to bring about
rather profound changes in cardiomyocyte
biology and the in vivo response to biome-
chanical stress. This strongly suggests a rheo-
stat-like role for C/EBPb, whereby small but
highly regulated changes in this factor are re-
flected in a broad downstream response in
the heart.
Among affected genes was also PGC1a,
a transcriptional coactivator that is important
for mitochondrial biogenesis and protection
against pathological heart stress (Arany et al.,2006; Finck and Kelly, 2007). As gain-of-function studies
in vitro did not suggest that PGC1a induces cardiomyocyte
hypertrophy, it is more likely that PGC1a acts via increasedmito-
chondrial gene expression and function.
A key mechanism by which C/EBPb controls Gata4 expres-
sion is through binding to SRF and sequestering this factor
from direct binding to the Gata4 (and a-MHC) promoters. This
mechanism of action may have rather broad implications for
cardiac biology considering the available data on the crucial
role of SRF in cardiomyocyte differentiation and the regulation
of expression of Tbx5, Gata, and Nkx2.5 (Akazawa and Komuro,
2003; Chai and Tarnawski, 2002). In fact, ablation of SRF is the
only known genetic knockout model that completely abolishes
cardiomyocyte differentiation (Fukushige et al., 2006). Possible
cardioprotective effects of C/EBPb reduction are also consistent
with recent reports that have described increased C/EBPb DNA
binding in pathological models for negative cardiac remodeling
(Oh et al., 2010).83, December 23, 2010 ª2010 Elsevier Inc. 1079
Figure 7. C/EBPb+/ Mice Have Cardiac Hypertrophy and Increased Proliferation Markers and Are Resistant to Pressure Overload
(A) Cardiomyocyte size was measured in cardiac tissue from wild-type (n = 5) and C/EBPb+/ (n = 7) mice using WGA membrane staining.
(B and C) Quantification of nuclear density assayed (B) and BrdU incorporation (C) from indicated mice.
(D) Typical image of Aurora B kinase (green) positive cardiomyocyte from C/EBPb+/ mouse heart, counterstained with anti-a-actinin (red) and dapi (blue).
(E) Immunohistochemistry against phosphohistone H3 (green) in primary cardiomyocyte from an adultC/EBPb+/mouse heart counterstained with a-actinin (red)
and dapi (blue).
(F) Wild-type and C/EBPb+/ (n = 6 and 7) mice subjected to TAC and assayed for fractional shortening at indicated times.
(G) Lung weight 52 days after TAC intervention.
(H) Kaplan-Meier plot of cardiac failure-free fraction at indicated times in wild-type and C/EBPb+/ mice following TAC procedure.
Error bars represent standard error of mean. *p < 0.05 versus respective control using Student’s t test. **p < 0.01. See also Figure S7.CITED4 was originally cloned 8 years ago (Braganc¸a et al.,
2002; Yahata et al., 2002), but very little is known about its func-
tion. We demonstrate here that CITED4 is expressed in the heart,1080 Cell 143, 1072–1083, December 23, 2010 ª2010 Elsevier Inc.and its expression is increased with exercise. CITED4 levels are
negatively regulated by C/EBPb expression, whereas experi-
mental alterations of CITED4 levels in primary cardiomyocytes
regulate proliferation. Forced expression of CITED4 also
increased levels of cyclin D1, which is known to drive cardiomyo-
cyte proliferation (Campa et al., 2008). Thus, it is highly plausible
that C/EBPb exerts its antiproliferative actions via inhibition of
CITED4 expression. However, we cannot exclude the possibility
that other pathways might also contribute.
C/EBPb reduction in the zebrafish embryo induced significant
proliferation that, together with data provided from mice,
suggests an evolutionarily conserved pathway in cardiomyo-
cytes. There was no effect on cardiomyocyte size in the fish
embryos; this could reflect a species difference or could be
explained by the particular developmental stage at which the
oligonucleotides were utilized.
The C/EBPb heterozygous mouse closely phenocopied the
endurance exercise model, as judged from cardiac hypertrophy,
cardiomyocyte proliferation, and expression of key genes of
cardiac function. In fact, 42% of the gene set analyzed was regu-
lated in the same manner by both of these perturbations in vivo.
The magnitude of the effect on hypertrophy at baseline,
however, was smaller than in the exercised mice, suggesting
that additional pathways are likely to contribute to the changes
induced in physiological hypertrophy.
Although exercise has well-known positive health effects,
possible benefits of physiological cardiac hypertrophy remain
unclear (such as improved outcome following pathological
provocations) in either mice or man. However, we were able
to demonstrate that hearts in C/EBPb heterozygous mice had
improved tolerance to pressure overload. This included resis-
tance to deterioration in cardiac function (fractional shortening)
after transverse constriction and improved survival. These
data are also important because transverse constriction is
a very selective stress to the heart and thus would not be
confounded by systemic effects of reduced C/EBPb in the total
body heterozygotes. Mechanistically, the increase in cardio-
myocyte proliferation could possibly contribute to the functional
resistance to cardiac dysfunction; such an effect would be in
accordance with resistance to injury connected to proliferation
observed in other systems (Bersell et al., 2009). However,
improved cellular energetics (via increased PGC1a expression),
physiological cellular hypertrophy, or other functional alter-
ations could also be important contributing factors. Better
understanding of the pathways affecting C/EBPb protein
expression, or drugs that suppress C/EBPb expression in the
heart, could be of significant clinical value in cardiac patholog-
ical states.EXPERIMENTAL PROCEDURES
Material
A list of utilized primers is presented in Table S2. Antibodies against PCNA,
tubulin, C/EBPb, actin, CITED4, ki67, phospho-Histone 3, Aurora B, BrDU,
b-tubulin, a-actinin, and nonimmune IgG were from Abcam. Antibodies to
SRF and C/EBPb were from Santa Cruz Biotechnology. HRP-conjugated
secondary antibodies were from Jackson ImmunoResearch Laboratories.
Alexa Flour (488 and 633) conjugated antibodies were from Invitrogen. Pre-
coated plates were from BD bioscience. Chamber slides for microscopy
were from Nalge Nunc International. BioPix iQ 2.0 were obtained from BioPix
AB (Gothenburg, Sweden). 35S-Methionine was purchased from Perkin Elmer
(Boston, MA). The chromatin immunoprecipitation kit was from Cell Signaling.CMice Cohorts
For the swimming experiments, 12-week-old B6 mice were used (purchased
from the Jackson Laboratory, Bar Harbor, ME). C/EBPb heterozygous mice
were purchased from the Jackson Laboratory, and all wild-type controls
usedwere age-matched littermates. The following IACUC-approved protocols
controlled the experiments: 005-2009, 110-2008, 056-2008, and #04650.
Swimming Exercise Protocol
Endurance exercise was carried out as described (Taniike et al., 2008). In brief,
mice swam in a ramp protocol starting at 10 min two times daily, with 10 min
increase each day until 90 min, two times per day was reached. The protocol
was ended after 14 days. The mice were closely observed at all times to avoid
relative hypoxia. With this protocol and using these mice strains, there were no
events of mice submerging under the water surface.
Transverse Aortic Constriction
Transverse aortic constriction (TAC) was carried out as described in Arany
et al. (2006) using a 27 gauge needle. Subsequently, mice were followed
weekly using echocardiography and sacrificed at fractional shortening < 30
(4 SD below baseline) and/or cachexia.
Echocardiographic Studies
Cardiac sonograms were carried out as described (Arany et al., 2006). In brief,
the heart was first visualized in long/short axis views followed by m-mode
analysis of short axis. Care was used to obtain exactly symmetrical short
axis images at the level of papillary muscles. At least three measurements
were obtained and averaged for every data point from each mouse.
RT-PCR
QPCR was carried out following standard procedures using SYBR green.
All data were normalized to 18S or indicated housekeeping gene, and quanti-
tative measures were obtained using the delta-delta-CT method. A list of
primers can be found in Figure S2.
Western Blot and Quantification and Coprecipitations
Protein amounts from all samples were assessed using the BCA-kit (Thermo
Scientific) followed by protein concentration normalization prior to all western
blot experiments. Western blot was carried out following standard procedure,
and final band intensity (QL-BG) was quantified using BioPix iQ (Bostro¨m et al.,
2010). All data was normalized to background and loading controls. Precipita-
tion of SRF was carried out as described in (Bostro¨m et al., 2007).
Adenoviral Construction and Preparation
Clones for CITED4 and C/EBPbwere purchased (Imagenes) as shuttle vectors
and moved to the pAD/CMV/V5-DEST vector using Gateway recombination
(Invitrogen) in accordance with manufacturer’s instructions. Adenoviruses
were then produced using the ViraPower Adenoviral Expression System
(Invitrogen), and viral stocks were purified using Vivapure Adenopack 100
(Sartorius Stedim Biotech). An MOI of 20 was used for all overexpression
experiments in primary cardiomyocytes. Characterization of overexpression
is shown in Figure S4 and Figure S6. Adenovirus expressing AKT and the
dnAKT was used as described in Matsui et al. (2003) and Nagoshi et al. (2005).
Immunohistochemistry from Frozen Sections
Tissues were snap frozen in OCT in liquid nitrogen and sectioned at 10 mm. For
staining, sections were fixed in 50% and 100% Acetone followed by washing
in PBS. Next, samples were incubated in 5% BSA, 0,1% Triton x-100, PBS
(buffert A) for 1 hr. After additional washing, slides were incubated overnight
with primary antibody in buffer A and thereafter in secondary antibody for
1 hr. Finally, slides were washed extensively in PBS for 30 min and mounted
in Prolong Gold with DAPI (Invitrogen).
Confocal Microscopy and Image Quantification
Samples were visualized using a Leica SP5 confocal microscope at 403
magnification using standard procedure. All imaging was performed with
group identity blinded whereby at least 20 random images were obtained
from each slide or group. Images were then quantified in BioPix iQ 2.0 inell 143, 1072–1083, December 23, 2010 ª2010 Elsevier Inc. 1081
accordance with manufacturer’s instructions (Bostro¨m et al., 2007; Hulte´n
et al., 2010).
BrdU Injections and Subsequent Staining Procedure
BrdUwas injected intraperitoneally 3 days prior to the end of the swim protocol
at 50 mg/kg. Cardiac sections were obtained as described above, and prior to
staining, the slides were incubated in 1 M HCl for 10 min on ice, followed by
2 M Hcl for 10 min room temperature and 20 min in 37 degrees. Slides were
then washed with 0.1 M Borate buffer 10 min and rinsed in PBS. Thereafter,
the previously described protocol for immunohistochemistry was utilized.
Rat Neonatal Primary Cardiomyocyte Culture and Transfections
Primary rat neonatal cardiomyocytes were prepared as described in Aoyama
et al. (2005) with gradient centrifugation purification of cardiomyocytes. siRNA
transfections were carried out using Lipofectamine 2000 (Invitrogen) as rec-
ommended by manufacturer and as described in Bostro¨m et al. (2007). Two
validated siRNA constructs against C/EBPb and CITED4 with respective
controls were purchased from Sigma Aldrich. Following examination of knock-
down and lack of off-target effects, the most effective construct was used for
subsequent studies.
Primary Adult Cardiomyocyte Preparation
Primary mouse cardiomyocytes were isolated following Langendorf perfusion
as described (Liao and Jain, 2007).
Nuclear Density Quantification
Nuclear density was assessed as described for ‘‘image quantification’’ above
using confocal images. The number of a-actinin-positive DAPI nuclei per area
of a-actinin-positive cells was used.
Treadmill Exercise
The acute exercise protocol included 40min of forced exercise on a 0% incline
treadmill (Columbus Instruments). The mice were trained twice briefly prior to
experiment. The long-term running was carried out 5 days per week for
4 weeks at a warmup speed of 5 m/min for 5 min. Every subsequent 5 min,
the speed was increased by 5 m/min until a maximal speed of 20 m/min was
reached to a maximum of 1 hr running. Estimate of maximal exercise capacity
was performed using a V02-max treadmill with a ramp protocol maximizing
running within 15 min at 20 degrees incline. Watts were calculated from the
incline per minute and mouse weight.
Cell Size Measurements and Quantification In Vitro and In Vivo
Cell size measurements from cardiac tissue were performed from WGA-
stained tissues (Invitrogen) in which only exactly cross-sectional cells (hexag-
onal) were used for BioPix iQ area measurements.
Protein Biosynthesis Assay
Protein biosynthesis was assessed in vitro after incubation with methionine-
free medium followed by a 1 hr pulse of 500 mCi/well 35S-Met. Cells were
then scraped, and protein was extracted using TCA (Bostro¨m et al., 2007).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed using the Simple ChIP kit (Cell
Signaling) in exact accordance with manufacturer’s instruction. In brief, ten
10 cm dishes were used in triplicates for all groups, and chromatin complexes
were fixed using formaldehyde. Next, nuclear fractionswere isolated, and DNA
was digested enzymatically. The quality and length of digested fragments
were verified on 1.5% gels. Finally, SRF was immunoprecipitated in parallel
with nonimmune IgG control, and DNA was extracted from complexes. DNA
was analyzed for presence of Gata4 or myh6 promoter fragments containing
SRE sites (primers used are presented in Table S2).
Zebrafish Experiments
An antisensemorpholino directed against C/EBPb or a control morpholino was
injected as described (Milan et al., 2006) at the one-cell stage. Embryos were
then analyzed at 24 or 36 hr as described. Morpholinos (Genetools) used were1082 Cell 143, 1072–1083, December 23, 2010 ª2010 Elsevier Inc.CCTCGTAAAAACCGGCCACTTCCAT for C/EBPb and CCTCTTACCTCAGT
TACAATTTATA for control.
Statistical Analysis
Data are presented as mean ± SEM unless otherwise indicated. Unpaired,
two-sided Student’s t test was used when indicated, with p < 0.05 considered
statistically significant. When assessingmultiple groups, one-way ANOVAwas
utilized with turkeys post hoc test. Kaplan-Meier statistics were performed
using Gehan-Breslow-Wilcoxon test. The statistical software used was
SPSS 17.1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and four tables and can be
found with this article online at doi:10.1016/j.cell.2010.11.036.
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